

Date: _____ Needs by date: _____

Patient Information:

Patient Name: _____

Address: _____

City, State, Zip: _____

Main Phone: _____ Alt. Phone: _____

Last 4 of SSN: _____ Height _____ in cm Weight _____ lbs kg

Date of Birth: _____ Male Female

Ship to: Patient _____ Office: _____ Other: _____

Prescriber Information:

Prescriber Name: _____

DEA: _____ NPI: _____ Group: _____

Address: _____

City, State, Zip: _____

Phone: _____ Fax: _____

Contact Person: _____

INSURANCE INFORMATION: PLEASE FAX A COPY OF PRESCRIPTION CARD AND MEDICAL CARD (FRONT AND BACK)

Clinical Information: Statement of Medical Necessity

Primary Diagnosis: _____ Date of Diagnosis: _____ Allergies: _____ NKDA Severity: Mild Moderate Severe Symptoms present \geq 1 year

ICD -10 code: M05.9 Rheumatoid arthritis with rheumatoid factor, unspecified Other ICD-10 Code: _____

Rheumatoid positive factor: _____ Joints Affected: _____ Number of Tender Joints: _____ Number of Swollen Joints: _____

Prior Failed medications: _____ Reason for discontinuation: _____ Current Medications: _____

Renal Dysfunction: Yes No Current Scr: _____ CrCl: _____ mL/min Lab Values: ANC: _____ ALC: _____ Platelets: _____ Hemoglobin: _____ AST: _____ ALT: _____

Does patient have a latex allergy? Yes No Has patient received TB/PPD test? Yes No PPD Test date: ____/____/____ Result: _____

Prescription Information

Medication	Dose/ Strength	Directions	Quantity	Refills
Actemra® (tocilizumab)	<input type="radio"/> 80 mg/ 4 mL <input type="radio"/> 400 mg/ 20 mL <input type="radio"/> 200 mg/ 10 mL <input type="radio"/> 162 mg/ 0.9 mL Prefilled Syringe	<input type="radio"/> IV: Infuse 4 mg/kg IV ONCE every 4 weeks (Max dose: 800mg) <input type="radio"/> IV: Infuse 8 mg/kg IV ONCE every 4 weeks (Max dose: 800mg) <input type="radio"/> SC < 100 kg: Inject 162 mg SC ONCE every OTHER week <input type="radio"/> SC < 100 kg: Inject 162 mg ONCE every week <input type="radio"/> SC \geq 100 kg: Inject 162 mg SC ONCE every week		
Amjevita™ (adalimumab-atto)	<input type="radio"/> 40 mg/0.8 mL Pen <input type="radio"/> 40 mg/0.8 mL Prefilled Syringe	<input type="radio"/> Inject 40 mg SC EVERY OTHER week <input type="radio"/> If NOT taking concomitant methotrexate may increase to inject 40 mg SC EVERY week		
Arava® (leflunomide)	<input type="radio"/> 10 mg Oral Tablets <input type="radio"/> 20 mg Oral Tablets	<input type="radio"/> Induction: Take 100 mg PO ONCE daily for 3 days (may omit if high risk for toxicity) <input type="radio"/> Maintenance: Take 20 mg ONCE daily (Max dose: 20 mg daily) <input type="radio"/> Maintenance: Take 10 mg ONCE daily		
Cimzia® (certolizumab pegol)	<input type="radio"/> 200 mg/mL Vial <input type="radio"/> Starter Kit 6 x 200 mg/mL <input type="radio"/> 200 mg/mL Prefilled Syringe	<input type="radio"/> Induction: Inject 400 mg (2 x 200 mg) SC ONCE at weeks 0, 2, and 4 <input type="radio"/> Maintenance: Inject 200 mg once EVERY OTHER week <input type="radio"/> Maintenance: Inject 400 mg (2 x 200 mg) once every 4 weeks		
Duexis® (Ibuprofen/famotidine)	<input type="radio"/> 800 mg/ 26.6 mg Oral Tablets	<input type="radio"/> Take one tablet three times daily		
Enbrel® (etanercept)	<input type="radio"/> 25 mg Vials <input type="radio"/> 50 mg/mL SureClick <input type="radio"/> 25 mg/0.5 mL Prefilled Syringe <input type="radio"/> 50 mg/mL Prefilled Syringe	<input type="radio"/> Inject 50 mg SC ONCE weekly		
Erelzi™ (etanercept-szszs)	<input type="radio"/> 25 mg/0.5 mL Prefilled Syringe <input type="radio"/> 50 mg/mL Prefilled Syringe <input type="radio"/> 50 mg/mL Sensoready Pen	<input type="radio"/> Inject 50 mg SC ONCE weekly		
Humira® (adalimumab)	<input type="radio"/> 40 mg/0.8 mL Pen <input type="radio"/> 40 mg/0.8 mL Prefilled Syringe <input type="radio"/> 40 mg/0.4 mL Pen <input type="radio"/> Humira® Citrate-free <input type="radio"/> 40 mg/0.4 mL Prefilled Syringe	<input type="radio"/> Inject 40 mg SC EVERY OTHER week <input type="radio"/> If NOT taking concomitant methotrexate may increase to inject 40 mg SC EVERY week		
Kevzara® (sarilumab)	<input type="radio"/> 150 mg/ 1.14 mL Prefilled Syringe <input type="radio"/> 200 mg/ 1.14 mL Prefilled Syringe	Check ANC, Platelets, ALT, AST <input type="radio"/> Inject 200 mg SC ONCE every 2 weeks		
Kineret® (anakinra)	<input type="radio"/> 100 mg/ 0.67 mL Prefilled Syringe	<input type="radio"/> Inject 100 mg SC ONCE daily		
Orencia® (abatacept)	<input type="radio"/> 125 mg/mL ClickJect <input type="radio"/> 250 mg Vial <input type="radio"/> 87.5 mg/ 0.7 mL Prefilled Syringe <input type="radio"/> 50 mg/ 0.4 mL Prefilled Syringe <input type="radio"/> 125 mg/mL Prefilled Syringe	<input type="radio"/> IV Induction: Infuse weight based dose: _____ mg IV every 0, 2, 4 weeks [< 60 kg = 500 mg; 60-100 kg = 750 mg; > 100 kg = 1000 mg] <input type="radio"/> IV Maintenance: Infuse weight based dose: _____ mg IV every 4 weeks [< 60 kg = 500 mg; 60-100 kg = 750 mg; > 100 kg = 1000 mg] <input type="radio"/> SC Maintenance: Inject 125 mg SC once weekly (may initiate SC with or without IV induction) - With IV induction start SC injection within 24 hrs of the IV infusion		
Inflixtra™ (infliximab-dyyb)	<input type="radio"/> 100 mg Vial Note: MUST be used in COMBINATION with METHOTREXATE	<input type="radio"/> Infuse 3 mg/kg = _____ mg IV at weeks 0, 2, and 6 weeks <input type="radio"/> Infuse 3 mg/kg = _____ mg IV at weeks 8 weeks <input type="radio"/> Incomplete response: Infuse _____ mg IV every _____ weeks [up to MAX of 10 mg/kg and a dosing interval of 4-8 weeks]		
Remicade® (infliximab)	<input type="radio"/> 100 mg Vial Note: MUST be used in COMBINATION with METHOTREXATE	<input type="radio"/> Infuse 3 mg/kg = _____ mg IV at weeks 0, 2, and 6 weeks <input type="radio"/> Infuse 3 mg/kg = _____ mg IV at weeks 8 weeks <input type="radio"/> Incomplete response: Infuse _____ mg IV every _____ weeks [up to MAX of 10 mg/kg and a dosing interval of 4-8 weeks]		
Rituxan® (rituximab)	<input type="radio"/> 10 mg/mL Vial Note: MUST be used in COMBINATION with METHOTREXATE Glucocorticoids given prior to treatment can decrease infusion reactions	<input type="radio"/> Induction: Infuse 1000 mg IV on day 1 and day 15 <input type="radio"/> Maintenance: Repeat (1000 mg on day 1 & 15) every 24 weeks <input type="radio"/> Maintenance: May Repeat (1000 mg on day 1 & 15) NO SOONER than every 16 weeks		
Simponi® (golimumab) Simponi® Aria™ (golimumab)	<input type="radio"/> 50 mg/ 4 mL vial Simponi Aria <input type="radio"/> 100 mg/ mL Autoinjector <input type="radio"/> 100 mg/ mL Prefilled Syringe <input type="radio"/> 50 mg/ 0.5 mL Autoinjector <input type="radio"/> 50 mg/ 0.5 mL Prefilled Syringe	<input type="radio"/> IV Induction: Inject 2 mg/ kg = _____ mg IV at week 0, 4, and 8 weeks <input type="radio"/> IV Maintenance: Inject 2 mg/ kg = _____ mg IV every 8 weeks <input type="radio"/> SC Maintenance: Inject 50 mg SC every 4 weeks		
Xeljanz® (tofacitinib) Xeljanz® XR (tofacitinib)	<input type="radio"/> 5 mg oral tablet IR <input type="radio"/> 11 mg oral tablet XR	- Check absolute lymphocyte, neutrophil, and hemoglobin counts prior to initiation <input type="radio"/> IR: Take 5 mg PO TWICE DAILY <input type="radio"/> XR: Take 11 mg PO ONCE DAILY		
Methotrexate	<input type="radio"/> 2.5 mg oral tablet <input type="radio"/> 50 mg/ 2 mL Vial <input type="radio"/> 250 mg/ 10 mL Vial <input type="radio"/> 1 g Vial <input type="radio"/> 100 mg/ 4 mL Vial	<input type="radio"/> Initial PO: Take 7.5 mg PO once weekly <input type="radio"/> Initial PO: Take 2.5 mg PO every 12 hrs x 3 doses per week <input type="radio"/> Initial IM: Inject 7.5 mg IM once weekly <input type="radio"/> Initial SC: Inject 7.5 mg SC once weekly <input type="radio"/> PO/ IM/ SC: Adjust dose gradually to optimal response (doses above 20 mg/week increase incidence of toxicity) _____ mg route: _____ once weekly		
Other:				

By signing this form and utilizing our services, you are authorizing Dottie's Pharmacy and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies. **Important Notice:** This form is intended to be delivered only to the named addressee. Confidential information may be protected health information under federal and state laws. If you receive this communication in error do not review, disclose, disseminate distribute or copy. Please notify the sender immediately and destroy all copies and any attachments.

Prescriber Signature: _____

Dispense as Written

Product Substitution Permitted

Date: _____